Increased expression of SCARF genes favoring SARS-CoV-2 infection in key target organs in CKD
Open Access
- 5 September 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 16 (12) , 2672-2682
Abstract
Background: Chronic kidney disease (CKD), especially diabetic CKD, is the condition that most increases the risk of lethal coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the underlying molecular mechanisms are unclear. SARS-CoV-2 and coronavirus-associated receptors and factors (SCARFs) regulate coronavirus cell entry and/or replication. We hypothesized that CKD may alter the expression of SCARF genes. Methods: A literature search identified 34 SCARF genes of which we selected 21 involved in interactions between SARS-CoV/SARS-CoV-2 and host cells, and assessed their mRNA expression in target tissues of COVID-19 (kidneys, lungs, aorta and heart) in mice with adenine-induced CKD. Results: Twenty genes were differentially expressed in at least one organ in mice with CKD. For 15 genes, the differential expression would be expected to favor SARS-CoV-2 infection and/or severity. Of these 15 genes, 13 were differentially expressed in the kidney and 8 were validated in human CKD kidney transcriptomics datasets, including those for the most common cause of CKD, diabetic nephropathy. Two genes reported to protect from SARS-CoV-2 were downregulated in at least two non-kidney target organs: Ifitm3 encoding interferon-induced transmembrane protein 3 (IFITM3) in lung and Ly6e encoding lymphocyte antigen 6 family member 6 (LY6E) in aorta. Conclusion: CKD, including diabetic CKD, is associated with the differential expression of multiple SCARF genes in target organs of COVID-19, some of which may sensitize to SARS-CoV-2 infection. This information may facilitate developing therapeutic strategies aimed at decreasing COVID-19 severity in patients with CKD.Keywords
Funding Information
- AstraZeneca Foundation
- FEDER (PI18/01 366, PI19/00 815, PI21/00 251)
- Sociedad Española de Nefrología (AC18/00 064)
- Sociedad Madrileña de Nefrologí (RD016/0009)
- FRIAT
- Comunidad de Madrid en Biomedicina (B2017/BMD-3686)
- Instituto de Salud Carlos III (RD21/0005/0001, PMP21/00 109)
- European Regional Development Fund (SPACE2-CV-COVID-CM)
This publication has 48 references indexed in Scilit:
- Urine metabolomics insight into acute kidney injury point to oxidative stress disruptions in energy generation and H2S availabilityJournal of Molecular Medicine, 2017
- The systemic nature of CKDNature Reviews Nephrology, 2017
- Mitogen-Activated Protein Kinase 14 Promotes AKIJournal of the American Society of Nephrology, 2016
- Tissue-based map of the human proteomeScience, 2015
- IFITM-Family Proteins: The Cell's First Line of Antiviral DefenseAnnual Review of Virology, 2014
- Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failureThe Lancet, 2014
- IFITM Proteins Restrict Viral Membrane HemifusionPLOS Pathogens, 2013
- Ifitm3 Limits the Severity of Acute Influenza in MicePLOS Pathogens, 2012
- IFITM3 restricts the morbidity and mortality associated with influenzaNature, 2012
- IFITM3 Inhibits Influenza A Virus Infection by Preventing Cytosolic EntryPLOS Pathogens, 2011